Short answer
Insmed Incorporated (INSM) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.2). Item 2.02 incorporates information by reference rather than presenting financial results in the provided text.
Insmed Incorporated 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 incorporates information by reference rather than presenting financial results in the provided text
- Investor-relevant earnings details require review of the referenced exhibits for fiscal year 2026 results
Item EX-99.1 · Exhibit EX-99.2
- Q2 2026 revenue $425.5M, up 296% year over year, driven by BRINSUPRI launch revenue of $309.2M
- BRINSUPRI guidance raised to $1.25B-$1.40B from at least $1B, signaling stronger-than-expected launch demand
- ARIKAYCE revenue $116.3M, up 8% year over year, with international growth of 19% partly offsetting U.S. growth of 2%
- Net loss narrowed to $13.2M from $321.7M, despite R&D of $210M and SG&A of $247.5M supporting pipeline and commercialization
- Peak revenue estimate raised above $14B across BRINSUPRI, TPIP, and ARIKAYCE; TPIP Phase 3 execution remains a key valuation catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insmed Incorporated 8-K filings
Get the next INSM 8-K as it lands
Follow INSM for push alerts, or ask the research agent what this filing means.